학술논문
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial
Document Type
Article
Author
de Latour, Régis Peffault ; Szer, Jeff; Weitz, Ilene C; Röth, Alexander; Höchsmann, Britta; Panse, Jens; Usuki, Kensuke; Griffin, Morag; Kiladjian, Jean-Jacques; de Castro, Carlos M; Nishimori, Hisakazu; Ajayi, Temitayo; Al-Adhami, Mohammed; Deschatelets, Pascal; Francois, Cedric; Grossi, Federico; Risitano, Antonio M; Hillmen, Peter
Source
In The Lancet Haematology September 2022 9(9):e648-e659
Subject
Language
ISSN
2352-3026